GSK - GlaxoSmithKline plc
41.19 0.00 (0.00%)
After hours: 5:07PM EDT
| Previous Close | 40.98 |
| Open | 41.42 |
| Bid | 41.01 x 1300 |
| Ask | 41.64 x 3200 |
| Day's Range | 41.07 - 41.73 |
| 52 Week Range | 36.41 - 42.47 |
| Volume | 3,360,404 |
| Avg. Volume | 2,314,315 |
| Market Cap | 102.582B |
| Beta (3Y Monthly) | 0.55 |
| PE Ratio (TTM) | 41.52 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.86 (4.60%) |
| Ex-Dividend Date | 2019-08-08 |
| 1y Target Est | N/A |
- Zacks
Top Analyst Reports for U.S. Bancorp, Duke Energy & Glaxo
Top Analyst Reports for U.S. Bancorp, Duke Energy & Glaxo
- Zacks
Pharma Stock Roundup: ABBV's Rinvoq Gets FDA Nod, BAYRY to Sell Animal Health Unit
FDA approves AbbVie's (ABBV) upadacitinib to be marketed as Rinvoq. Bayer (BAYRY) is set to divest its Animal Health unit to Elanco for $7.6 billion in a cash-and-stock deal.
- Reuters
UPDATE 2-GSK builds oncology pipeline as drug shown to help myeloma patients
GlaxoSmithKline said an experimental multiple myeloma treatment has shown a meaningful response in patients that have run out of three previous treatment options, in a boost for the British drugmaker's cancer drug business. Two doses of belantamab mafodotin helped subdue the disease in adults who had received three prior treatments for multiple myeloma, a cancer of the white blood cells, GSK said on Friday. GSK sold its approved oncology drugs to Novartis in 2014, but has staged a comeback in cancer treatment with a deal to buy U.S. firm Tesaro for $5.1 billion last year and an agreement in February to pay up to 3.7 billion euros ($4.09 billion) to Germany's Merck KGaA for the rights to a next-generation immunotherapy.
- Zacks
Glaxo Submits First Regulatory Application for Daprodustat
Glaxo (GSK) seeks approval for its anemia candidate, daprodustat, in Japan. Moreover, once every two months administration of cabotegravir and rilpivirine shows non-inferiority to once a month administration in HIV patients in a clinical study.
- Reuters
GSK's long acting HIV injection gets boost from study
ViiV, in which Pfizer and Shionogi have small stakes, is working on two-drug combinations and will use the lower drug burden in comparison with three-drug cocktails such as Gilead's Biktarvy as its main selling point to patients and physicians. It is banking on longer-term studies to yield hard evidence of fewer side effects over time.
- Reuters
UPDATE 2-GSK's long acting HIV injection gets boost from study
GlaxoSmithKline's experimental HIV injection is as effective when given every other month as monthly, according to a study, a convenience that could help the British drugmaker in its battle against a rival drug from Gilead Sciences. GSK's two-drug injection was as effective as a monthly dose of the same regimen in maintaining viral suppression at 48 weeks in a late-stage study, said ViiV Healthcare, GSK's HIV unit. ViiV, in which Pfizer and Shionogi have small stakes, is working on two-drug combinations and will use the lower drug burden in comparison with three-drug cocktails such as Gilead's Biktarvy as its main selling point to patients and physicians.
- GuruFocus.com
3 Large-Cap Stocks With High Dividend Yields
GlaxoSmithKline tops the list Continue reading...
- Motley Fool
Ionis Pharmaceuticals Looks to Partners to Pay the Bills
Royalties are nice, but licensing, milestone, and option payments are getting it done for this biotech.
- Zacks
Should Value Investors Consider GlaxoSmithKline (GSK) Stock?
Let's see if GlaxoSmithKline (GSK) stock is a good choice for value-oriented investors right now from multiple angles.
- American City Business Journals
GSK's new pharma president carries Merck, Pfizer experience
With the change of leadership for GSK's pharmaceutical business, the Triangle won't necessarily be losing its GSK leader.
- Motley Fool
AnaptysBio Prepares for a Potential Gear Shift
During the second quarter, the company upgraded the safety net under its lead candidate.
- Zacks
Agenus (AGEN) Q2 Earnings Miss Estimates, Revenues Beat
Agenus (AGEN) reports wider-than-expected loss and beats sales estimates in the second quarter of 2019.
- GuruFocus.com
Kahn Brothers' Top 6 Buys in the 2nd Quarter
Firm of the late Irving Kahn releases portfolio, top buy is Merck Continue reading...
- American City Business Journals
Local companies impacted by trade war-fueled stock market decline
Among the Philadelphia region’s largest 20 publicly traded companies, three in the chemical industry experienced the biggest dips in midday trading.
- Simply Wall St.
It Might Be Better To Avoid GlaxoSmithKline plc's (LON:GSK) Upcoming 1.1% Dividend
GlaxoSmithKline plc (LON:GSK) is about to trade ex-dividend in the next 2 days. You can purchase shares before the 8th...
- Thomson Reuters StreetEvents
Edited Transcript of GSK.L earnings conference call or presentation 24-Jul-19 1:00pm GMT
Q2 2019 GlaxoSmithKline PLC Earnings Call
- Zacks
Emergent (EBS) Earnings Miss in Q2, Revenues Beat Estimates
Emergent's (EBS) earnings miss estimates in the second quarter of 2019 while revenues surpass the mark.
- Zacks
Pharma Stock Roundup: PFE, MRK, LLY Q2 Earnings, Upjohn-MYL Merger
AbbVie (ABBV), Merck (MRK), Pfizer (PFE), Lilly (LLY) report Q2 results. Pfizer announces plan to merge off-patent unit, Upjohn with Mylan to form new company.
- Zacks
Theravance (TBPH) Q2 Loss Narrower, Revenues Beat Estimates
Theravance (TBPH) reports narrower-than-expected loss and beats on sales in the second quarter of 2019.
- American City Business Journals
GSK, Pfizer complete deal to combine consumer health brands
Under the terms of the agreement, GSK will own 68% of the consumer health joint venture and Pifzer will own the remaining 32%.
- Benzinga
The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 1) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Odonate ...
